Katja Elisabeth Odening
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Katja Elisabeth Odening has a total of 316 co-authors. Here are the top co-authors by number of shared publications:
Manfred Zehender
Department of Cardiology and Angiology I, University Heart Center Freiburg, University Medical Center Freiburg, Freiburg, Germany
15 shared publications- Michael Brunner
Department of Cardiology, University Heart Centre, University Hospital Freiburg , Hugstetter Str. 55, 79106 Freiburg, Freiburg
11 shared publications Christoph Bode
Department of Cardiology and Angiology I, University Heart Center Freiburg, Medical Faculty, University of Freiburg, Freiburg, Germany
10 shared publications- Miriam Barbieri
Translational Cardiology, Institute of Physiology and Department of Cardiology, University Hospital Bern, University of Bern , Bühlplatz 5, Bern 3012
9 shared publications Gideon Koren
Brown University Health
8 shared publicationsAlessandro Castiglione
Translational Cardiology, Department of Cardiology, Inselspital, University Hospital Bern, University of Bern, Bern, Switzerland
7 shared publications
Latest Publications
- Open Access
Multi-scale electrophysiological characterization of human cardioids reveals progressive maturation
Background: Human induced pluripotent stem cell-derived cardiomyocytes are valuable for cardiac disease modelling and drug testing but remain limited by immature structural and electrophysiological properties in conventional two-dimensional cultures. Three-dimensional cardiac models, including cardioids, provide a more physiological environment through multicellular organization and enable tissue-level functional analysis. Their electrophysiological properties and maturation, however, remain incompletely characterized. Methods: We performed an integrated electrophysiological characterization of human cardioids over the first three weeks of maturation using sharp microelectrode recordings, calcium transient measurements, whole-cell patch clamp recordings, immunofluorescence, transcriptomic analysis, and pharmacological interventions. Results: During maturation, cardioids exhibited progressive electrophysiological maturation, characterized by more physiological resting membrane potentials (−54.0±3.1mV to −68.1±1.2mV), increased action potential amplitude (73.5±4.8mV to 101.7±2.1mV) and upstroke velocity (44.3±5mV/ms to 86.6±8.4mV/ms), and shorter action potential duration (178.9±8.7ms to 144.0±4.8ms at 1Hz stimulation). These changes were associated with progressively increased I Na density and enhanced SCN5A mRNA and Na v 1.5 protein expression, consistent with progressive maturation of cardiac excitability. I Kr current and KCNH2 /hERG expression were already present at early maturation stages and remained stable, as evidenced by preserved sensitivity to dofetilide-blockade. Pharmacological inhibition of barium- and HMR-sensitive currents altered resting membrane and/or action potential characteristics in intact cardioids, whereas in isolated cardiomyocytes classical I K1 remained undetectable and I Ks was small, highlighting a certain degree of persisting immaturity of the model. Conclusions: These findings demonstrate that human cardioids undergo progressive electrophysiological maturation and provide complementary tissue- and cellular-level insights into cardiac function, establishing their suitability for investigating I Na and I Kr -related cardiac pathologies.
Open AccessMulti-scale electrophysiological characterization of human cardioids reveals progressive maturation
Background: Human induced pluripotent stem cell-derived cardiomyocytes are valuable for cardiac disease modelling and drug testing but remain limited by immature structural and electrophysiological properties in conventional two-dimensional cultures. Three-dimensional cardiac models, including cardioids, provide a more physiological environment through multicellular organization and enable tissue-level functional analysis. Their electrophysiological properties and maturation, however, remain incompletely characterized. Methods: We performed an integrated electrophysiological characterization of human cardioids over the first three weeks of maturation using sharp microelectrode recordings, calcium transient measurements, whole-cell patch clamp recordings, immunofluorescence, transcriptomic analysis, and pharmacological interventions. Results: During maturation, cardioids exhibited progressive electrophysiological maturation, characterized by more physiological resting membrane potentials (−54.0±3.1mV to −68.1±1.2mV), increased action potential amplitude (73.5±4.8mV to 101.7±2.1mV) and upstroke velocity (44.3±5mV/ms to 86.6±8.4mV/ms), and shorter action potential duration (178.9±8.7ms to 144.0±4.8ms at 1Hz stimulation). These changes were associated with progressively increased I Na density and enhanced SCN5A mRNA and Na v 1.5 protein expression, consistent with progressive maturation of cardiac excitability. I Kr current and KCNH2 /hERG expression were already present at early maturation stages and remained stable, as evidenced by preserved sensitivity to dofetilide-blockade. Pharmacological inhibition of barium- and HMR-sensitive currents altered resting membrane and/or action potential characteristics in intact cardioids, whereas in isolated cardiomyocytes classical I K1 remained undetectable and I Ks was small, highlighting a certain degree of persisting immaturity of the model. Conclusions: These findings demonstrate that human cardioids undergo progressive electrophysiological maturation and provide complementary tissue- and cellular-level insights into cardiac function, establishing their suitability for investigating I Na and I Kr -related cardiac pathologies.
- 1 October 2026
- Published by American Physiological Society in American Journal of Physiology-Heart and Circulatory Physiology
- Vol. 331 (4) , H1402-H1418
Variable expressivity in long QT syndrome type 2 rabbits defines a low threshold for therapeutic I Kr restoration
In a transgenic rabbit model of long QT syndrome type 2 exhibiting variable phenotypic expressivity, we show that partial I Kr restoration is associated with reduced ventricular arrhythmias. Combined electrophysiological mapping, single-cell recordings, and computational modeling identify a low range of I Kr restoration that may reduce arrhythmogenicity, whereas AAV9 studies demonstrate that mosaic cardiac gene expression approaching this range is achievable, highlighting the translational relevance of partial I Kr restoration and challenges of safe in vivo gene delivery.
- 1 October 2026
- Published by American Physiological Society in American Journal of Physiology-Heart and Circulatory Physiology
- Vol. 331 (4) , H1402-H1418
Variable expressivity in long QT syndrome type 2 rabbits defines a low threshold for therapeutic I Kr restoration
In a transgenic rabbit model of long QT syndrome type 2 exhibiting variable phenotypic expressivity, we show that partial I Kr restoration is associated with reduced ventricular arrhythmias. Combined electrophysiological mapping, single-cell recordings, and computational modeling identify a low range of I Kr restoration that may reduce arrhythmogenicity, whereas AAV9 studies demonstrate that mosaic cardiac gene expression approaching this range is achievable, highlighting the translational relevance of partial I Kr restoration and challenges of safe in vivo gene delivery.
- 25 September 2026
- Published by Oxford University Press (OUP) in Cardiovascular Research
Spatial APD heterogeneity: new insights into the role of sinus activation time
- 25 September 2026
- Published by Oxford University Press (OUP) in Cardiovascular Research
Spatial APD heterogeneity: new insights into the role of sinus activation time
- Open Access
- 15 April 2026
- Published by Elsevier in Pharmacological Research
- Vol. 227, 108189
SGK1-inhibition restores cardiac repolarization in LQT2 rabbits and LQT3 mice by reducing late sodium current
- 15 April 2026
- Published by Elsevier in Pharmacological Research
- Vol. 227, 108189
Open AccessSGK1-inhibition restores cardiac repolarization in LQT2 rabbits and LQT3 mice by reducing late sodium current
- Open Access
- 11 March 2026
- Published by Elsevier in IJC Heart & Vasculature
- Vol. 64, 101901
Differential effects of non-selective and cardio-selective beta-blocker therapy on ECG parameters in long QT syndrome type 1
- 11 March 2026
- Published by Elsevier in IJC Heart & Vasculature
- Vol. 64, 101901
Open AccessDifferential effects of non-selective and cardio-selective beta-blocker therapy on ECG parameters in long QT syndrome type 1
- Open Access
- 19 January 2026
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 28 (2)
Mechano-electrical feedback in transgenic rabbit models of long QT syndrome Type 2 and short QT syndrome Type 1
Aims: Electromechanical coupling and mechano-electrical feedback (MEF) are crucial for cardiac function, but their pro-arrhythmic roles in short and long QT syndromes (SQT1 and LQT2) are not fully understood. We aimed to evaluate MEF-induced electrical changes, their arrhythmic impact, and the involvement of stretch-activated channels (SACs) in transgenic rabbit models of SQT1 and LQT2. Methods and results: Patch-clamp and fluorescence imaging were used to analyse action potential duration (APD), Ca²⁺ transients, and contractility in ventricular cardiomyocytes (VCMs) from LQT2, SQT1 and wild-type (WT) rabbits. LQT2 cells showed prolonged APD and Ca²⁺ transients, increased early afterdepolarizations, Ca²⁺ oscillations, and impaired mechanics compared to WT and SQT1. The cellular electromechanical window (Ca²⁺-transient duration minus APD) was more negative in LQT2 and more positive in SQT1 than in WT. QTc prolonged with preload/afterload increase and decreased with preload reduction across all genotypes, but MEF-induced QTc changes and dispersion were most pronounced in LQT2. Ex vivo Langendorff experiments showed that increased right ventricular (RV) pressure prolonged APD and QTc in WT hearts. This was attenuated by the SAC blocker GSMTx4, suggesting a role for SACs in MEF. In silico models of human VCMs including SACs confirmed higher vulnerability to stretch/MEF-induced arrhythmias, including re-entry, in SQT1 and LQT2. Conclusion: Mechano-electrical feedback-induced electrical changes, partly mediated by SACs, occur in WT, SQT1, and LQT2, but MEF effects are strongest in LQT2. Mechano-electrical feedback induces pro-arrhythmic effects in silico more prominently in LQT2 and SQT1 than in WT, highlighting the potential pro-arrhythmic role of MEF in a vulnerable electrophysiological substrate.
- 19 January 2026
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 28 (2)
Open AccessMechano-electrical feedback in transgenic rabbit models of long QT syndrome Type 2 and short QT syndrome Type 1
Aims: Electromechanical coupling and mechano-electrical feedback (MEF) are crucial for cardiac function, but their pro-arrhythmic roles in short and long QT syndromes (SQT1 and LQT2) are not fully understood. We aimed to evaluate MEF-induced electrical changes, their arrhythmic impact, and the involvement of stretch-activated channels (SACs) in transgenic rabbit models of SQT1 and LQT2. Methods and results: Patch-clamp and fluorescence imaging were used to analyse action potential duration (APD), Ca²⁺ transients, and contractility in ventricular cardiomyocytes (VCMs) from LQT2, SQT1 and wild-type (WT) rabbits. LQT2 cells showed prolonged APD and Ca²⁺ transients, increased early afterdepolarizations, Ca²⁺ oscillations, and impaired mechanics compared to WT and SQT1. The cellular electromechanical window (Ca²⁺-transient duration minus APD) was more negative in LQT2 and more positive in SQT1 than in WT. QTc prolonged with preload/afterload increase and decreased with preload reduction across all genotypes, but MEF-induced QTc changes and dispersion were most pronounced in LQT2. Ex vivo Langendorff experiments showed that increased right ventricular (RV) pressure prolonged APD and QTc in WT hearts. This was attenuated by the SAC blocker GSMTx4, suggesting a role for SACs in MEF. In silico models of human VCMs including SACs confirmed higher vulnerability to stretch/MEF-induced arrhythmias, including re-entry, in SQT1 and LQT2. Conclusion: Mechano-electrical feedback-induced electrical changes, partly mediated by SACs, occur in WT, SQT1, and LQT2, but MEF effects are strongest in LQT2. Mechano-electrical feedback induces pro-arrhythmic effects in silico more prominently in LQT2 and SQT1 than in WT, highlighting the potential pro-arrhythmic role of MEF in a vulnerable electrophysiological substrate.
- 14 October 2025
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 47 (13) , 1622-1624
Towards a personalized, mechanism-based risk prediction of post-operative atrial fibrillation
- 14 October 2025
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 47 (13) , 1622-1624
Towards a personalized, mechanism-based risk prediction of post-operative atrial fibrillation
- Open Access
- 30 August 2025
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 47 (2) , 199-213
AAV9-mediated KCNH2 suppression-replacement gene therapy in a transgenic rabbit model of type 1 short QT syndrome
Background and Aims: Type 1 short QT syndrome (SQT1) is a genetic channelopathy caused by gain-of-function variants in KCNH2, resulting in shortened cardiac repolarization and QT intervals, which predispose patients to ventricular arrhythmias and sudden cardiac death. This study aimed to investigate the therapeutic efficacy of KCNH2-specific suppression-and-replacement (KCNH2-SupRep) gene therapy in a transgenic rabbit model of SQT1. Methods: KCNH2-SupRep was developed by combining a KCNH2-shRNA with its corresponding shRNA-immune KCNH2-cDNA into an AAV9 vector, delivered directly into the aortic root (1 × 1010 vg/kg). Therapeutic efficacy was evaluated in vivo by electrocardiogram, ex vivo by optical mapping, and at cellular levels by patch-clamp, calcium imaging, and qPCR in ventricular cardiomyocytes (VCMs). Results: In vivo, KCNH2-SupRep normalized the heart rate-corrected QT interval (QTc) in SQT1 rabbits, without affecting repolarization heterogeneity. Ex vivo, KCNH2-SupRep corrected the action potential duration (APD90) and resolved the increased apicobasal APD90 heterogeneity observed in untreated (UT)-SQT1 hearts, supporting an antiarrhythmic effect, which was further validated by reduced re-entry formation in silico. At cellular levels, KCNH2-SupRep prolonged APD90 in VCMs from SupRep-SQT1 rabbits closer to wildtype levels compared with UT- and sham-SQT1. Additionally, KCNH2-SupRep restored the cellular surrogate of the electro-mechanical window and normalized IKr in nearly 50% of VCMs, in line with a 50%–60% suppression of the mutant KCNH2 transcript. Conclusions: This proof-of-concept study is the first to demonstrate the efficacy of gene therapy for SQT1 in a medium-sized animal model. KCNH2-SupRep gene therapy successfully corrected the pathologic phenotype in vivo, ex vivo, and at cellular levels in transgenic SQT1 rabbits.
- 30 August 2025
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 47 (2) , 199-213
Open AccessAAV9-mediated KCNH2 suppression-replacement gene therapy in a transgenic rabbit model of type 1 short QT syndrome
Background and Aims: Type 1 short QT syndrome (SQT1) is a genetic channelopathy caused by gain-of-function variants in KCNH2, resulting in shortened cardiac repolarization and QT intervals, which predispose patients to ventricular arrhythmias and sudden cardiac death. This study aimed to investigate the therapeutic efficacy of KCNH2-specific suppression-and-replacement (KCNH2-SupRep) gene therapy in a transgenic rabbit model of SQT1. Methods: KCNH2-SupRep was developed by combining a KCNH2-shRNA with its corresponding shRNA-immune KCNH2-cDNA into an AAV9 vector, delivered directly into the aortic root (1 × 1010 vg/kg). Therapeutic efficacy was evaluated in vivo by electrocardiogram, ex vivo by optical mapping, and at cellular levels by patch-clamp, calcium imaging, and qPCR in ventricular cardiomyocytes (VCMs). Results: In vivo, KCNH2-SupRep normalized the heart rate-corrected QT interval (QTc) in SQT1 rabbits, without affecting repolarization heterogeneity. Ex vivo, KCNH2-SupRep corrected the action potential duration (APD90) and resolved the increased apicobasal APD90 heterogeneity observed in untreated (UT)-SQT1 hearts, supporting an antiarrhythmic effect, which was further validated by reduced re-entry formation in silico. At cellular levels, KCNH2-SupRep prolonged APD90 in VCMs from SupRep-SQT1 rabbits closer to wildtype levels compared with UT- and sham-SQT1. Additionally, KCNH2-SupRep restored the cellular surrogate of the electro-mechanical window and normalized IKr in nearly 50% of VCMs, in line with a 50%–60% suppression of the mutant KCNH2 transcript. Conclusions: This proof-of-concept study is the first to demonstrate the efficacy of gene therapy for SQT1 in a medium-sized animal model. KCNH2-SupRep gene therapy successfully corrected the pathologic phenotype in vivo, ex vivo, and at cellular levels in transgenic SQT1 rabbits.